250 related articles for article (PubMed ID: 37386633)
1. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.
Xie J; Li S; Li Y; Li J
BMC Health Serv Res; 2023 Jun; 23(1):706. PubMed ID: 37386633
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.
Cher BP; Goh S; Aziz MIA; Wong G; Ng Chee Hui R; Ong BS; Ng KH
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):217-225. PubMed ID: 38149409
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.
Lang Y; Chai Q; Tao W; Liao Y; Liu X; Wu B
Breast; 2023 Apr; 68():173-180. PubMed ID: 36780838
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China.
Wang L; Liu L; Zhang Z; Li F; Ruan Y; He Y; Huang J; Zheng X
Clin Breast Cancer; 2024 Apr; ():. PubMed ID: 38760263
[TBL] [Abstract][Full Text] [Related]
5. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
[TBL] [Abstract][Full Text] [Related]
6. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
7. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
8. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
Baek G; Jung L; Duong A; Gralow J
J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
[TBL] [Abstract][Full Text] [Related]
9. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
Schreiber AR; Andress M; Diamond JR
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
[No Abstract] [Full Text] [Related]
10. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
[TBL] [Abstract][Full Text] [Related]
11. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
Bardia A; Hurvitz SA; Rugo HS; Brufsky A; Cortes J; Loibl S; Piccart M; Cowden J; Spears P; Carey LA
Future Oncol; 2021 Oct; 17(30):3911-3924. PubMed ID: 34467774
[TBL] [Abstract][Full Text] [Related]
12. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
[TBL] [Abstract][Full Text] [Related]
13. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis.
Wu Y; Hu S; Liu X; Chen Y; Luan J; Wang S
Cost Eff Resour Alloc; 2024 Apr; 22(1):32. PubMed ID: 38659013
[TBL] [Abstract][Full Text] [Related]
15. Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US.
Chen J; Han M; Liu A; Shi B
Front Oncol; 2021; 11():734594. PubMed ID: 34778047
[TBL] [Abstract][Full Text] [Related]
16. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
[TBL] [Abstract][Full Text] [Related]
17. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer.
Kang C
Target Oncol; 2024 Mar; 19(2):289-296. PubMed ID: 38446351
[TBL] [Abstract][Full Text] [Related]
18. Role of sacituzumab govitecan in solid tumors.
Veeraballi S; Khawar Z; Aslam HM; Muzaffar M
J Oncol Pharm Pract; 2022 Oct; 28(7):1617-1623. PubMed ID: 35404158
[TBL] [Abstract][Full Text] [Related]
19. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
Zangardi ML; Spring LM; Nagayama A; Bardia A
Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
[TBL] [Abstract][Full Text] [Related]
20. Sacituzumab Govitecan: First Approval.
Syed YY
Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]